美凱龍(601828.SH):擬發行2022年度第一期中期票據
格隆匯9月25日丨美凱龍(601828.SH)公佈,2022年9月25日,公司第四屆董事會第五十次臨時會議審議通過了《關於公司發行2022年度第一期中期票據的議案》,同意公司向中國銀行間市場交易商協會申請註冊發行中期票據,募集資金不超過人民幣30億元(含30億元),資金將用於償還公司及控股子公司有息負債、補充流動資金等符合法律法規的用途;並審議通過了《關於提請股東大會授權董事會全權辦理2022年度第一期中期票據發行相關事宜的議案》,為保證公司本次發行的順利進行,同意公司董事會提請股東大會授權董事會及其授權人士全權辦理與本次發行有關的全部事宜。該事項尚須提請股東大會審議批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.